Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.HeartBeam, Inc. (BEAT) Q3 2026 Earnings Call Transcript
HeartBeam Reports Third Quarter 2026 Results
HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time
HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG
HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026
HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology
HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment
HeartBeam, Inc. (NASDAQ:BEAT) Stock Has Consensus Price Target of $4.00
HeartBeam, Inc. Letter to Shareholders
HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript
HeartBeam Reports Second Quarter 2026 Results
HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time
Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now
HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device
Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home